PhaseOne Health Collaborates with Nonprofit Humanitarian Organization to Supply NovaBay Pharmaceuticals’ Phase One® Skin and Wound Cleanser to Ukraine
May 05 2023 - 6:50AM
Business Wire
PhaseOne Health announces it has provided PhaseOne Skin and
Wound Cleanser (PhaseOne) as part of a $3 million donation of
medical supplies to Ukraine in partnership with the nonprofit
HelpingUkraine.us. Formulated with NovaBay Pharmaceuticals’ (NYSE
American: NBY) patented, stable hypochlorous acid, PhaseOne (0.025%
hypochlorous acid solution) is a proprietary wound care product
used for cleansing and irrigation as part of surgical procedures,
as well as for treating certain wounds, burns, ulcers and other
injuries. PhaseOne is distributed in the U.S. by PhaseOne
Health.
“We are proud to provide PhaseOne to aid in the treatment of
wounds and burns suffered by Ukrainian soldiers and civilians as
their conflict with Russia enters its second year,” said PhaseOne
Health Managing Director Kristopher Perkins, who traveled to
Ukraine to train local medical professionals on proper storage, use
and application of PhaseOne. “I’ve seen firsthand the challenges
that Ukrainians are facing and am impressed by their spirit and
their ability to cope with the horrors of war. We are honored to
play a small role in helping those who have been injured.”
“It is a privilege to have PhaseOne made available to
Ukrainians, whether they are serving on the frontlines of battle or
are being impacted by the relentless bombings of civilian targets,”
said Justin Hall, CEO of NovaBay Pharmaceuticals. “PhaseOne is
ideal for use in Ukrainian medical facilities due to its stable,
potent, broad-spectrum formulation. It is non-toxic, non-irritating
and non-sensitizing to skin and new tissue and can be used on
wounds as frequently as needed. Through our proprietary
manufacturing process and amber glass bottle, we ensure the safest,
purest, most powerful hypochlorous acid wound cleanser on the
market.”
About PhaseOne Health and PhaseOne Skin and Wound
Cleanser
Based in Nashville, PhaseOne Health licenses, markets and
distributes PhaseOne, a registered trademark of NovaBay
Pharmaceuticals, Inc. Laboratory tests show that PhaseOne kills the
bacteria that infect wounds to neutralize the toxins that impede
healing and destroy healthy tissue. Hypochlorous acid is part of
the body’s natural immune system that combats acute infections and
promotes the healing of chronic wounds. Among the benefits of
hypochlorous acid is its ability to penetrate and kill biofilm,
which represents a significant barrier to wound healing. PhaseOne’s
pure hypochlorous acid formulation is without the toxic chemicals
that may be found in other wound care products.
The effectiveness of PhaseOne is independently documented in the
study “Comparative Antimicrobial Activity of Commercial Wound Care
Solutions on Bacterial and Fungal Biofilms” (Harriott, PhD et al),
which was published in the peer-reviewed journal Annals of Plastic
Surgery.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 OTC dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230505005012/en/
PhaseOne Health
info@phaseonehealth.com
NovaBay Pharmaceuticals
info@novabay.com
LHA Investor Relations Jody Cain jcain@lhai.com 310-691-7100
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024